MyKronoz Introduces ZePods Fashionable and Colorful True Wireless Earbuds, Together with a New Line of Affordable Smartwatches
26.2.2019 14:38:00 EET | Business Wire | Press release
Swiss wearable brand MyKronoz today announced ZePods, its first collection of true wireless earphones, unveiled at Mobile World Congress Barcelona 2019. Offering an impressive sound quality, up to 15 hours of playtime, stylish design with 6 vibrant colors and matching USB-C charging case, intuitive touch control to manage music, calls and voice commands thanks to its Bluetooth 5.0 technology - MyKronoz’s first true wireless earbuds will come in two versions with distinctive design and features:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190226005577/en/
ZePods - Wireless TWS earbuds (Photo: MyKronoz)
- ZePods, with a USB-C charging case boasting the familiar look of a sleek lighter. Available in April 2019 for a MSRP of 79,90€/$ only.
- ZePods+, with a Qi-certified wireless charging case whose shape has been greatly inspired by Swiss traditional pocket-watch. Available H2 2019 for a MSRP of 99,90€/$.
"Building on our Swiss DNA for design and our strong background in wearable technology, we believe that MyKronoz has a tremendous opportunity to seize in the flourishing market of wireless earbuds. The launch of ZePods appears as a natural and strategic evolution for our company to leverage expertise in developing affordable consumer-driven products and diversify to offer a full ecosystem." said Boris Brault, MyKronoz Founder and CEO.
In addition to ZePods, MyKronoz goes back to basics of affordable fashion wearables with a complete new line starting at 29.90 €/$, featuring activity tracker, smartwatches, sport smartwatches and hybrids to cater a large and diversified audience. Among the new collection, 4 products highlights:
- ZeTrack - a slim and full-featured HR activity tracker with color touchscreen. MSRP: 29.90€/$ - Launch date: end of March 2019.
- ZeNeo - a real powerful smartwatch with mic & speaker that looks like a sleek activity tracker. MSRP: 59.90€/$ - Launch date: end of April 2019.
- ZeRound3 Lite - the go-to smartwatch designed for your active lifestyle. MSRP: 79.90€/$ - Launch date: end of April 2019.
- ZeRound3 - the genuinely stylish connected smartwatch with AMOLED display. MSRP: 99.90€/$ - Launch date: end of March 2019.
The rest of the range includes ZeSport2, a multi-sport GPS smartwatch, already available at a MSRP of 149.90€/$. MyKronoz will continue to innovate in H2 2019 with ZePop - the hybrid smartwatch that blends fashion and tech. MSRP: 129,90€/$ as well as ZeTime2 - a stainless steel hybrid smartwatch with microphone, AMOLED display and real mechanical hands. MSRP: 199,90€/$.
ZePods, as well as the MyKronoz full new wearable collection will be on display and available for demos on the MWC 2019 show foor at the MyKronoz booth in the Congress Square (Booth #CS118) February 25-28th, 2019.
ABOUT MYKRONOZ:
MyKronoz is part of BOW Group, a global player in lifestyle consumer products, operating worldwide in the design and wearables markets with its 2 brands: MyKronoz and LEXON.
Since July 2015, BOW has opened up its capital to Next Stage AM, then, in 2017 to PM Equity Partner - the corporate venture fund of Philip Morris International. MyKronoz ZeTime has convinced over 40,000 backers in more than 100 countries and became the world's highest funded hybrid smartwatch with more than $8 million raised, as well as the largest crowdfunding campaign ever from a European company and the most backed product of 2017 on Kickstarter.
BOW Group has now more than 100 talents spread across four office locations: Paris, Geneva, Miami and Shenzhen.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190226005577/en/
Contact information
International media:
Annabel
Corlay
press@mykronoz.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom